CBL-514

DRUG4 trials

Sponsors

Caliway Biopharmaceuticals Co., Ltd.

Conditions

Subcutaneous Fat

Phase 1

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

CompletedNCT04699669

Caliway Biopharmaceuticals Co., Ltd.Subcutaneous Fat

Start: 2018-11-27End: 2019-08-20Updated: 2021-01-07

Phase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

CompletedNCT04575467

Caliway Biopharmaceuticals Co., Ltd.Subcutaneous Fat

Start: 2020-12-09End: 2021-12-08Updated: 2024-08-09

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

CompletedNCT04698642

Caliway Biopharmaceuticals Co., Ltd.Subcutaneous Fat

Start: 2020-02-03End: 2020-11-12Updated: 2021-01-08

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

CompletedNCT05234736

Caliway Biopharmaceuticals Co., Ltd.Subcutaneous Fat

Start: 2022-02-11End: 2022-06-09Updated: 2026-05-22